OCULAR THERAPEUTIX, INC (OCUL) Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Ocular Therapeutix, Inc. NASDAQ:OCUL Healthcare · Biotechnology
Prev close $6.59 Open $6.25 Now $6.41 VOL 574K $ Vol $3.53M RVOL 0.21x
Mkt Cap $1.41B
VOL 574K sh
$ Vol $3.53M
RVOL 0.21×
Press Release ● Major ⚠ 4
Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business Highlights
Ocular Therapeutix reported Q3 2026 net revenue of $12.9 million (down from $14.5 million a year ago) and a net loss of $94.8 million, or $(0.42) per share, versus $(69.4) million or $(0.38) a year earlier, driven by a jump in R&D spending to $74.8 million.
The lead story is regulatory: the AXPAXLI NDA for wet AMD remains on track for 4Q 2026 under the 505(b)(2) pathway following a positive September Pre-NDA meeting, supported by positive SOL-1 Phase 3 data and an interim SOL-R Week 52 safety analysis also coming in 4Q.
The SOL-R primary endpoint was moved from Week 56 to Week 40, pushing topline efficacy results to 1Q 2028; interim screening data show ~20% of otherwise eligible subjects excluded for early persistent fluid, which management frames as validating the trial's patient-enrichment design.
Cash stands at $530.6 million with runway into 2028, and the board adds Riad Sherif, MD (Oculis CEO, ex-Alcon/Novartis) as Seung Suh Hong steps down at year-end, adding commercial depth ahead of a potential AXPAXLI launch.
• 2h ago AI analysis › Press Release
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix granted inducement equity awards to eight newly hired non-executive employees under its 2019 Inducement Stock Incentive Plan.
The grants, effective November 2, 2026, include options on 35,775 shares at a $6.73 exercise price and RSUs covering 11,725 shares, with standard four-year and three-year vesting schedules.
This is a routine Nasdaq 5635(c)(4) hiring-related disclosure with no material financial or pipeline implications.
• 3d ago AI analysis › Press Release
Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026
Ocular Therapeutix will host a conference call and webcast on Monday, November 9, 2026 at 8:00 AM ET to discuss Q3 2026 financial results for the quarter ended September 30.
The release contains no financial figures or business updates, only dial-in and webcast details, with a replay archived at least 30 days.
Pipeline context in the release notes AXPAXLI is in Phase 3 trials for wet AMD and diabetic retinal disease, alongside commercial product DEXTENZA.
• 7d ago AI analysis › Press Release
Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences
Ocular Therapeutix announced participation in several November 2026 investor and scientific conferences, including a UBS Global Biopharma Conference fireside chat on November 17.
CEO Pravin Dugel will present the fireside chat, and CSO Jeffrey Heier will present at The Empire Forum and an nAMD symposium in New York.
The release contains no new clinical or financial data; AXPAXLI remains in Phase 3 trials for wet AMD and diabetic retinal disease.
• 11d ago AI analysis › Press Release
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix granted inducement equity awards to fifteen newly hired non-executive employees under its 2019 Inducement Stock Incentive Plan, effective October 5, 2026.
The grants include options to purchase 70,150 shares at $7.25 per share (equal to the grant-date closing price) and RSUs covering 22,900 shares, vesting over three to four years.
This is a routine hiring-related disclosure with no bearing on the company's clinical pipeline or financial performance.
• 1mo ago AI analysis › Press Release
Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences
Ocular Therapeutix announced its participation in several October 2026 scientific and investor conferences, including a fireside chat at the Chardan 10th Annual Healthcare Conference on October 20 led by CEO Pravin U. Dugel.
Of note, topline outcomes from the Phase 3 SOL-1 trial of hydrogel-formulated AXPAXLI in neovascular AMD will be presented at the Innovate Retina meeting on October 8 and at AAO sessions on October 9 and 12.
The release contains no new clinical or financial data; it is a scheduling notice, though the SOL-1 data presentations may be a near-term catalyst for the stock.
• 1mo ago AI analysis › Press Release
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • 1mo ago Press Release ⚠ 4
Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD
Ocular Therapeutix completed a positive Pre-NDA meeting with the FDA for AXPAXLI (OTX-TKI) in wet AMD, confirming alignment on the content and format of the filing and keeping the NDA submission on track for the fourth quarter of 2026.
The NDA will be built on Week 52 efficacy and safety data from the Phase 3 SOL-1 superiority trial, which met its primary endpoint with high statistical significance in February 2026, plus interim SOL-R safety data, confirmatory evidence, and subjects with multiple AXPAXLI injections to support repeat dosing.
Filing under the 505(b)(2) pathway could shorten FDA review by up to 60 days versus a traditional 505(b)(1) submission, and commercial readiness is accelerating ahead of a potential 2027 launch, where AXPAXLI could become the first tyrosine kinase inhibitor approved for wet AMD.
• 1mo ago AI analysis › Press Release
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences
Ocular Therapeutix announced it will participate in the Wells Fargo 21st Annual Healthcare Conference and the Baird 2026 Global Healthcare Conference, where CEO Pravin Dugel will host a fireside chat.
At upcoming scientific meetings including the Retina Society Annual Meeting and Euretina Congress, the company and investigators will present Phase 3 SOL-1 trial results for OTX-TKI in neovascular age-related macular degeneration.
Additional presentations at the Ophthalmology Futures Forums and Euretina Innovation Spotlight will focus on the company's retina pipeline and its commercial product DEXTENZA.
• 2mo ago AI analysis › Press Release
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix appointed Beth Rada as Senior Vice President of Government Affairs and Public Policy, granting inducement equity awards to secure her employment.
The compensation package includes a non-statutory stock option for 85,000 shares at an exercise price of $9.24 and 28,000 restricted stock units, subject to standard four-year and three-year vesting schedules respectively.
These grants were issued under the company’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
• 2mo ago AI analysis › Press Release
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix granted inducement equity awards to eight newly hired non-executive employees, consisting of options to purchase 53,975 shares and RSUs for 17,450 shares.
The options have a ten-year term with a four-year vesting schedule and an exercise price of $8.40 per share, equal to the closing price on the grant date.
The grants were made under the company's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
• 3mo ago AI analysis › Press Release ⚠ 1
Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights
Ocular Therapeutix reported Q2 revenue of $13.5 million, flat year-over-year, with a net loss of $78.8 million or $0.35 per share.
The company confirmed its AXPAXLI wet AMD NDA submission remains on track for Q4 2026, utilizing the 505(b)(2) pathway which could accelerate the review timeline by up to 60 days.
A new post-hoc analysis of the SOL-1 trial demonstrated up to a 72% reduction in treatment burden compared to aflibercept, while cash balance stands at $598.6 million providing runway into 2028.
• 3mo ago AI analysis › Press Release
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • 4mo ago Press Release
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
Ocular Therapeutix announced its participation in the OIS Retina Innovation Summit and the ASRS Annual Meeting in Montréal, as well as the HC Wainwright Ophthalmology Virtual Conference later in July.
Presentations at the ASRS meeting will feature Phase 3 SOL-1 trial results for OTX-TKI in neovascular age-related macular degeneration and analyses of real-world anti-VEGF treatment patterns.
CEO Pravin U. Dugel is scheduled to participate in a fireside chat at the HC Wainwright conference on July 22, which will be webcast on the company's website.
• 4mo ago AI analysis › Press Release
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix granted inducement equity awards to newly hired SVP Kelley Allison, consisting of options to purchase 85,000 shares and RSUs for 28,000 shares.
The option grants have an exercise price of $8.99 per share and vest over four years, while the RSUs vest over three years.
These awards were made under the company's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq rules.
• 4mo ago AI analysis › Press Release ● Major ⚠ 2
Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026
Ocular Therapeutix announced it has reached alignment with the FDA to submit a New Drug Application for AXPAXLI in wet AMD during the fourth quarter of 2026.
The submission will leverage the 505(b)(2) pathway to potentially accelerate the review timeline by up to 60 days, relying on the robust efficacy and safety data from the SOL-1 trial supported by interim safety data from SOL-R.
The company also extended the SOL-R trial to evaluate long-term superiority endpoints, now expecting topline results in the first quarter of 2028, while streamlining its diabetic retinopathy program to prioritize the single HELIOS-3 trial.
• 4mo ago AI analysis › Press Release
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix granted inducement equity awards to seven newly hired non-executive employees.
The grants consist of 51,775 stock options and 16,950 restricted stock units, totaling 68,725 shares.
Options were priced at $8.93 per share, matching the closing price on the grant date of June 1, 2026, and vest over four years.
• 5mo ago AI analysis › Press Release
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026
Ocular Therapeutix will present updates on its lead asset OTX-TKI (AXPAXLI) at Clinical Trials at the Summit 2026 in Las Vegas on June 12-13.
Presentations will cover the science, efficacy outcomes in neovascular AMD, safety profile, and the HELIOS program update in nonproliferative diabetic retinopathy.
CEO Pravin Dugel will also participate in a fireside chat and a panel on bringing novel treatments to market. No new clinical data is released in this announcement.
• 5mo ago AI analysis › Press Release
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
Ocular Therapeutix will host an Investor Day on June 17, 2026, in New York City, featuring presentations from senior leadership and roundtable discussions with prominent retinal disease experts.
The event will highlight the NDA submission plan for AXPAXLI in wet AMD, updates on the SOL-R and SOL-X trials, and the registrational program for diabetic retinopathy.
A live webcast will be available on the company’s website, with a replay archived for at least 30 days following the presentation.
• 5mo ago AI analysis › Press Release
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix granted inducement equity awards to Amy Ricca, its newly appointed SVP and Head of HR.
The package includes options for 75,000 shares at $9.28 and 25,000 RSUs, vesting over three to four years.
The grants comply with Nasdaq Listing Rule 5635(c)(4) and are part of the company's 2019 Inducement Stock Incentive Plan.
• 5mo ago AI analysis › Press Release ● Critical
Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights
Ocular Therapeutix reported Q1 2026 revenue of $10.8 million, flat year-over-year, but highlighted significant clinical progress for its lead asset AXPAXLI.
The Phase 3 SOL-1 trial met its primary superiority endpoint with a p-value of 0.0006, showing that 65.9% of AXPAXLI patients maintained vision at Week 52 compared to 44.2% for aflibercept.
With a cash balance of $666.7 million funding operations into 2028, the company is accelerating commercial preparations and plans to submit an NDA for AXPAXLI, while SOL-R data is expected in Q1 2027.
• 6mo ago AI analysis › Press Release
Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD
Ocular Therapeutix enrolled the first patient in the SOL-X long-term extension trial for AXPAXLI in wet AMD.
The 36-month open-label study allows patients who completed the SOL-1 or SOL-R trials to receive an additional three years of treatment every 24 weeks.
Management believes the trial will demonstrate improved long-term visual outcomes and a dramatically reduced treatment burden compared to current anti-VEGF therapies.
• 6mo ago AI analysis › Press Release
Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026
Ocular Therapeutix announced that it will report its first quarter 2026 financial results and discuss recent business progress via a conference call on May 5, 2026.
The event is scheduled to begin at 8:00 AM ET, with live access available through webcast and dial-in lines for domestic and international participants.
A replay of the webcast will be archived and accessible on the company's investor relations website for at least 30 days following the presentation.
• 6mo ago AI analysis › Press Release
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences
Ocular Therapeutix announced its schedule for upcoming investor and scientific conferences in May 2026.
Investor events include fireside chats at the Bank of America Health Care Conference and the Stifel Virtual Ophthalmology Forum.
Scientific presentations will feature Phase 3 SOL-1 trial results for OTX-TKI at the ARVO Annual Meeting and updates on the TKI program at the Retina World Congress.
• 6mo ago AI analysis › Press Release
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
Ocular Therapeutix announced plans to host an Investor Day on June 17, 2026, in New York City.
The event will feature senior leadership and retinal key opinion leaders, with live and virtual access scheduled to begin at 2:00 PM ET.
The company's pipeline highlights include Phase 3 candidate AXPAXLI for wet AMD and FDA-approved product DEXTENZA.
• 6mo ago AI analysis › 
